Accendra Health Inc. Common Stock (ACH)
Stock · NYSE · Health Care
$0.2254as of 10/16/2026
Price chart
ACH Signal Track Record
How signals performed across all stocks →What ACH's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | -3.2% | 43% | September 18, 2026 |
| Bollinger Band Breakdown | 23 | -2.2% | 43% | September 18, 2026 |
| Bollinger Band Breakout | 23 | -6.9% | 35% | July 16, 2026 |
| 200-Day Moving Average TouchActive now | 9 | -6.6% | 33% | August 4, 2026 |
| Any 20-session window (baseline) | -3.5% | 43% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ACH
Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States. It offers a range of products and services for in-home care and delivery for diabetes treatment; home respiratory therapy, including home oxygen and non-invasive ventilation services; obstructive sleep apnea treatment, such as continuous positive airway pressure and bi-level positive airway pressure…
- Sector
- Health Care
- Industry
- Medical Specialities
- Employees
- 6,500
- Website
- www.accendrahealth.com
Fundamentals
- 1-day range
- $0.2169$0.2893
- Market cap
- $223.62M
- P/E (trailing)
- —
- P/E (forward)
- 2.76
- EPS (trailing)
- $-3.93
- Dividend yield
- —
- Beta
- 1.53
- Avg. volume
- 1.55M
- Ex-dividend date
- December 14, 2021
- Dividend pay date
- December 31, 2021
How Accendra Health Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 20, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
Accendra Health Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ACHAccendra Health Inc. Common Stock$0.24▼ 7.69%Market cap $223.62MP/E —$0.2615$5.6
- BDSXBiodesix Inc. Common Stock$23.66▼ 4.25%Market cap $228.86MP/E —$5.26$31.97
- YDESYD Bio Limited Ordinary Shares$5.92▼ 12.17%Market cap $167.45MP/E —$1.7$22
- XGNExagen Inc. Common Stock$7.72▼ 9.81%Market cap $159.64MP/E —$2.59$12.23
- TLSITriSalus Life Sciences Inc. Common Stock$3.63▼ 6.92%Market cap $299.10MP/E —$2.2$7.95
- KEQUKewaunee Scientific Corporation Common Stock$32.93▲ 2.30%Market cap $108.73MP/E 11.26$32$46.57
- TLSIWTriSalus Life Sciences Inc. Warrant$0.8799▼ 2.23%Market cap $101.95MP/E —$0.4405$1.85
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ACH Accendra Health Inc. Common Stock | $223.62M | — | $0.24 | ▼ 7.69% | $0.2615$5.6 |
| BDSX Biodesix Inc. Common Stock | $228.86M | — | $23.66 | ▼ 4.25% | $5.26$31.97 |
| YDES YD Bio Limited Ordinary Shares | $167.45M | — | $5.92 | ▼ 12.17% | $1.7$22 |
| XGN Exagen Inc. Common Stock | $159.64M | — | $7.72 | ▼ 9.81% | $2.59$12.23 |
| TLSI TriSalus Life Sciences Inc. Common Stock | $299.10M | — | $3.63 | ▼ 6.92% | $2.2$7.95 |
| KEQU Kewaunee Scientific Corporation Common Stock | $108.73M | 11.26 | $32.93 | ▲ 2.30% | $32$46.57 |
| TLSIW TriSalus Life Sciences Inc. Warrant | $101.95M | — | $0.8799 | ▼ 2.23% | $0.4405$1.85 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Accendra Health Says It Received NYSE Notice Over $1.00 Minimum Share Price Rule; Will Consider Reverse Split If Necessarybenzinga · 10/9/2026
- Accendra Health Receives Continued Listing Standard Notice from NYSE; Intends to Cure Deficiency and Return to Compliance with NYSE Listing StandardYahoo · 10/9/2026
- New Strong Sell Stocks for October 9thYahoo · 10/9/2026
- Accendra Health Form 13G Shows Bank Of America Reports 10.8% Stake In Co. As Of Sept. 30Benzinga · 10/7/2026
- New Strong Sell Stocks for October 6thYahoo · 10/6/2026
- Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company’s Next Chapter of GrowthYahoo · 9/17/2026
- Accendra Health Names Kenneth Gardner-Smith as Next President and CEO; Expected To Assume the Role Early in Q4 of 2026, succeeding Edward PesickaBenzinga · 9/17/2026
- Accendra Health Appoints Kenneth Gardner-Smith As President And CEO, Succeeding Edward PesickaBenzinga · 9/17/2026
Insider Activity
Insider Actions →- Kenneth Gardner-Smith · October 5, 2026 · Grant283.6K
- Jonathan A. Leon · September 23, 2026 · Tax Withholding4.3K @ $0.85
- Heath H. Galloway · May 15, 2026 · Tax Withholding966 @ $3.04
- Perry A. Bernocchi · May 15, 2026 · Tax Withholding7.9K @ $3.04
- Jonathan A. Leon · May 15, 2026 · Tax Withholding1.8K @ $3.04
- Edward A. Pesicka · May 15, 2026 · Tax Withholding17.7K @ $3.04
- Teresa L. Kline · May 14, 2026 · Grant31.2K
- Mark A. Beck · May 14, 2026 · Grant31.2K
- Kenneth Gardner-Smith · May 14, 2026 · Grant31.2K
- Stephen W. Klemash · May 14, 2026 · Grant31.2K
- Bingham Gwendolyn M · May 14, 2026 · Grant31.2K
Institutional Ownership
March 31, 2026
- Total shares held
- 60.47M
- Total value held
- $135.63M
- Institutional holders
- 137
- Unknown13.10M
- Unknown5.24M
- Unknown3.64M
- Unknown3.41M
- Unknown3.37M
- Unknown3.31M
- Unknown3.28M
- Unknown2.61M
- Unknown1.84M
- Unknown1.79M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Accendra Health Receives NYSE Continued Listing Notice
Accendra Health received a notice from the NYSE regarding continued listing standards, with the company stating its intent to cure the deficiency. This regulatory development adds pressure to a stock that is already trading near its 52-week low. Additionally, Bank of America disclosed a 10.8% stake in the company as of September 30.
Accendra Health Receives NYSE Continued Listing Notice. Accendra Health received a notice from the NYSE regarding continued listing standards, with the company stating its intent to cure the deficiency. This regulatory development adds pressure to a stock that is already trading near its 52-week low. Additionally, Bank of America disclosed a 10.8% stake in the company as of September 30.